Novavax, Inc. (NASDAQ:NVAX) shares are trading higher by 7.3% at $237.68, potentially on continued strength after the company on Friday highlighted the publication of positive Phase 2b malaria vaccine data.
Novavax is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
Posted In:
